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Recent publication of the Medicines and Healthcare products Regulatory Agency
(MHRA) in the United Kingdom has strengthened the regulatory measures for valproate
medicines. It highlights the importance of making women of childbearing age with
epilepsy aware of the teratogenic risks of valproate and encourages the withdrawal of
it from those currently prescribed. While a significant directive, it raises concerns of not
having considered the impact on special populations such as women with Intellectual
Disability (ID). While it is important that women with ID are not excluded from such
safety initiatives, due caution needs to be taken on a case by case basis preferably,
to ensure their best interests are central to the decision making. Many women with
moderate to profound ID cannot have informed consented sexual relationships not to
mention cognitive incapability to make informed choices on medication suitability. These
women are at potential risk of having their epilepsy control undermined due to the
MHRA directives. Around 30% of people with moderate to profound ID have seizures
of which 60% are considered treatment resistant. In this vulnerable population changes
to medication without clear clinical and social insights could lead to increased harm
levels. This paper enumerates the challenges of application of the new directive to
these special populations and proposes a pathway based on individual cognitive ability
to provide informed consent to facilitate the continuation or removal of valproate. It is
important not to lose sight of individual circumstances and the importance of working
collaboratively toward providing person center care.
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INTRODUCTION
The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom have
recently strengthened the regulatory measures for valproate medicines (1). The new regulations
contraindicate the use of valproate medicines in girls or women of child bearing age unless they
participate in the Pregnancy Prevention Programme (Appendix 1).
Watkins et al. Valproate MHRA Guidance: Limitations and Opportunities
The MHRA regulations recognize that it is not safe for some
women to discontinue valproate prescription in pregnancy and
doing so may in fact pose considerable risk to both the mother
and the fetus. In such scenarios it may be more appropriate
to continue treatment under specialist care (1). There are
however exceptional circumstances and practical implications
that have not been fully considered by the MHRA regulations.
Notwithstanding the requirement for clear documentation and
informed consent, it is important not to lose sight of individual
circumstances and the importance of working collaboratively
toward providing person center care (2).
VALPROATE-EVIDENCE OF TERATOGENIC
RISK
Valproate is a known serious teratogen associated with a risk of
major congenital malformations (MCM) (Table A1). A MCM is
defined as an abnormality of an essential anatomical structure
interfering with function or requiring major intervention (3).
The evidence base for valproate teratogenicity is largely based on
observational studies of people with epilepsy.
In addition to the MCM risk in children of mothers
prescribed valproate there is an increased association with
neurodevelopmental, cognitive, and behavioral sequelae.
Intelligence Quotient (IQ) assessments have consistently shown
lower scores associated with valproate exposure in comparison
to other antiepileptic drugs (AEDs). The Neurodevelopmental
Effects of Antiepileptic Drugs (NEAD) study was a prospective
observational study in which cognitive assessments were
completed on children at a 6 year interval. The assessors
were unaware of which antiepileptic drug was prescribed for
the mother in each case. Valproate exposure was associated
with lower IQ scores than other commonly prescribed AEDs
(Lamotrigine, Carbamazepine, and Phenytoin). This was
evidenced across domains of verbal ability, non-verbal ability,
memory, and executive function. Adverse effects on cognition
were more prominent in association with high dose valproate
prescription which was not observed in the other AEDs
investigated (4). This cohort also demonstrated statistically
significant lower scores on a range of adaptive functioning
assessments, and a specific increase in association with attention
deficit hyperactivity disorder (ADHD) (5). A population-based
study of all live births in Denmark for 1996–2006 compared
exposure to valproate to autism spectrum disorder (ASD)
diagnosis. The relative risk of ASD diagnosis in this population
was over 4% (6).
Both with respect to the MCMs, and the neurodevelopmental
concerns, there appear to be a clear dose dependent relationship
(5, 7–9). A family history of MCMs or neurodevelopmental
problems contributes to the risk on an individual basis.
Therefore, women prescribed low dose valproate without
additional risk factors may be at lower risk. The totality of
the long-term risks associated with valproate remains unknown
as regulatory bodies have not followed the trajectory of
development and health in all children exposed to this teratogen
during pregnancy.
VALPROATE PRESCRIPTION IN
EXCEPTIONAL CIRCUMSTANCES
For some women of child-bearing age on valproate treatment
participation in the Pregnancy Prevention Programme may not
be appropriate (Appendix 2). In these scenarios there are still
situations in which a Risk Acknowledgment Form will need to
be signed by the individual and specialist following informed
discussion. However, the current Risk Acknowledgment Form
does not allow for these circumstances. For a woman who is
trying to conceive, or one who is sexually abstinent the “Effective
contraception is essential while taking valproate,” and specific
emphasis on invasive methods (coil, implants or sterilization)
is clearly inappropriate and potentially discriminatory. Another
vulnerable group of women are those who lack capacity to
fully participate in the decision making process. In these
scenarios the only option may be for the specialist to
amend the form by hand and justify those areas that are
not applicable.
VALPROATE IN PEOPLE WITH EPILEPSY
AND INTELLECTUAL DISABILITY
People with epilepsy and ID require specific consideration.
The prevalence of epilepsy in people with ID is far higher
than the general population (10). The etiological influences
are complex and include genetic abnormalities (including
epilepsy syndromes), underlying structural changes, and co-
morbid neurological deficits (11). This complexity contributes
to the fact that people with epilepsy and ID are refractory to
antiepileptic medication. A population-based prevalence study
has shown that up to 68% of people with epilepsy and ID may
be treatment resistant (12). Therefore, any change in medication
will require careful consideration for those individuals who
are stable on monotherapy valproate or a combination of
valproate and other AEDs. In addition, people with ID and
epilepsy commonly suffer psychiatric co-morbidities (13, 14).
Therefore, valproate is often considered a first line treatment
for its additional mood stabilizing benefits to help moderate the
pharmacological load.
The evidence base for prescribing antiepileptic medication
for people with epilepsy and ID is limited and there are no
randomized controlled trials or Class I evidence (15). The
prescription of valproate in this population is largely guided by
evidence extrapolated from large robust investigations in the
general population such as the SANAD study (16). Valproate
remains a first-line drug for generalized seizures, and there is
also evidence that people with ID and treatment resistant seizures
may be more responsive (15).
CONSENT
Where an individual lacks capacity to make informed decisions
around their antiepileptic medication a formal best interest’s
process should be followed (Pathway A1). If lack of capacity
is temporary (emergency situation) the individual should be
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notified of treatment and if treatment continues, informed
consent should be obtained at the earliest opportunity.
A proportion of womenwith ID and epilepsy will permanently
lack capacity to make informed decisions about their medical
care including the prescription of AEDs. Capacity should be
assessed formally for each decision as set out in the guidance
from the Mental Capacity Act (MCA) (2005). In accordance
with the principles of the MCA, all practicable steps should be
taken to engage the individual in the decision making process.
This includes making reasonable adjustments and the use of
communication aids and/or assistance from specialist speech
and language therapists. Impaired capacity may include difficulty
understanding the risk and benefits of the medication; difficulties
in retaining relevant information for long enough to make
a decision; difficulties in weighing up relevant information;
difficulties in communicating any decision.
Where individuals are assessed and deemed to lack capacity
to make an informed decision, it is important to attempt to
understand their views and involve the individual in decision
making process where possible and appropriate. This could
be facilitated through purposely designed valproate resources
for the ID community, and the opportunity for advocacy
support to help the individual make their voice heard and
challenge decisions. Family and caregivers are an important
source of information, however, it is essential to appreciate the
vulnerability of this population. There is an inherent risk of
decisions being imposed on individuals without any involvement
in the decision making process.
In the MHRA regulations there are two clear decisions that
require informed consent-valproate treatment, and participation
in the Pregnancy Prevention Programme. Capacity to provide
informed consent should be assessed for these two decisions
individually. Many women with more moderate to profound ID
will not only lack capacity to consent to medical treatment but
also lack capacity to consent to sexual relationships. Participation
in the Pregnancy Prevention Programme includes adherence to
invasive contraceptive methods. These contraceptive methods
are associated with their own risks and therefore participation
may not be in an individual’s best interest. For individuals who
lack capacity to consent to sexual relationships pregnancy would
raise serious safeguarding concerns, implying sexual abuse.
Approaching discussion around this topic unnecessarily can
potentially be very distressing for the individual, their families,
and caregivers.
CONCLUSION
The regulatory measures for valproate prescription from the
MHRA are based on a weight of evidence that has guided
clinical practice for some time. However, there are individuals
and scenarios that have not been fully considered in the
regulation. There are womenwhomay consider the contraceptive
methods advised by the MHRA unacceptable for personal,
religious, or health reasons. In such circumstances the regulations
discriminate against these women who are in a position to make
fully informed decisions around treatment choice. The MHRA
guidance to only prescribe valproate in rare cases for patients who
are resistant or intolerant of other treatments does not consider
the complex reality of clinical practice including:
1. Women who have not trialed an alternative antiepileptic
drug nor do they wish to for fear of potential life
threatening consequences of uncontrolled seizures, therefore
their response to other treatment is unknown.
2. Women under-going a valproate treatment change in
pregnancy-a slow titration process where the consequences of
polytherapy and impact on teratogenicity and seizure control
are largely unknown.
The regulations neglect to consider women who lack capacity
to make informed decisions around medical care. This includes
some women with ID who are more likely to have treatment
resistant seizures and multiple physical and psychiatric co-
morbidities. There are also practical considerations that will
impact on primary care services, community pharmacists and
secondary services. People on stable doses of valproate, with
and without capacity, and even where there is recent and
comprehensive documentation about counseling and decision
making, are now being referred back into already pressured
secondary care services to complete a Risk Acknowledgment
Form. All now require annual specialist review purely for this
purpose. Once the form is completed (including following
a best interest’s process for individuals who lack capacity)
where prescription of valproate continues, there should be
no need to change existing arrangements for prescribing
undertaken in primary care. For those who lack capacity, where
a best interest decision is established and discussions with the
community pharmacist completed- this should be placed on
an individual’s patient medication record to prevent further
unnecessary questioning every time valproate is dispensed
which could cause inappropriate distress. In adhering to the
MHRA guidelines with the current Risk Acknowledgment
Form it is challenging to deliver person center care. Without
modification, the current Risk Acknowledgment Form does
not recognize scenarios where enforced invasive contraception
maybe inappropriate, and in which individuals lack capacity
to consent to treatment where a Best Interest process is
required. In fact it is in contradiction to the MCA (2005) as
no individual has the authority to sign the form to consent on
behalf of another adult, unless there are formal legal powers
in place.
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